Press Releases
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD’s Breast AI Suite helps her detect the breast cancers radiologists fear most NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound…
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
Company’s ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities NASHUA, N.H., July 10, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it is showcasing its ProFound AI…
iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its Breast AI Suite…
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. Highlights:…
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced…
iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference
iCAD’s AI solution minimizes interval cancers and overcomes challenges associated with digital breast tomosynthesis NASHUA, N.H., May 3, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density…
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
NASHUA, N.H., May 1, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
Kathy Schilling, MD, Boca Raton Regional Hospital, to discuss how ProFound AI helped nine dedicated breast radiologists find 23% more cancers, without increasing the rate of recalls NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,…
New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection and Reveals Critical Clues to Inform Clinical Decisions
New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today…
Cleveland Clinic Radiologist Presents Use Case of iCAD’s Breast AI Technology at Siemens Healthineers Innovations for Healthcare Professionals Education Symposium
Dr. Laura Dean to discuss how AI solutions minimizes interval cancers and helps clinicians overcome challenges associated with digital breast tomosynthesis Laura Dean, MD, a radiologist at the Cleveland Clinic, will discuss the use of iCAD’s Breast AI Suite for patients and clinicians in a presentation titled “Minimizing Interval…